RxDoctor Payments Data

Kinga Huzella, MD

Ophthalmology · Hagerstown, MDNPI 1659371888

Payments from drug & device makers

$6,202in general payments, 2019–2025

Across 262 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sun Pharmaceutical Industries Inc.$993
  • Mallinckrodt Hospital Products Inc.$935
  • Bausch & Lomb Americas Inc.$488
  • Tarsus Pharmaceuticals, Inc.$453
  • ANI Pharmaceuticals, Inc.$286
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$6,10498%
  • Education$982%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,202 in reported general payments places this provider in the 75th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$390,360
Medicare patients
1,039
Services billed
5,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine98$97,946
XdemvyLotilaner31$55,614
LumiganBimatoprost62$30,911
XiidraLifitegrast24$22,319
RhopressaNetarsudil Mesylate25$13,590
Cyclosporine31$12,309
Loteprednol Etabonate60$9,471
CombiganBrimonidine Tartrate/Timolol15$7,620
Tobramycin-DexamethasoneTobramycin/Dexamethasone123$6,297
SimbrinzaBrinzolamide/Brimonidine Tart22$5,846
Latanoprost336$5,759
Prednisolone Acetate125$3,679
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$3,672
Brimonidine Tartrate60$3,663
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat77$2,246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$1,003$136,476175 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$453$55,61431 claims
Bausch & Lomb Americas Inc.Xiidra$488$22,31924 claims
Aerie Pharmaceuticals, Inc.Rhopressa$28$13,59025 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$246$9,47160 claims
AlconSimbrinza$196$5,84622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →